Cargando…
Comparative Outcomes of a Transthyretin Amyloid Cardiomyopathy Cohort Versus Patients With Heart Failure With Preserved Ejection Fraction Enrolled in the TOPCAT Trial
BACKGROUND: Transthyretin cardiac amyloidosis (ATTR‐CM), found in 6% to 15% of cohorts with heart failure with preserved ejection fraction, has long been considered a rare disease with poor prognosis. New treatments have made it one of the few directly treatable causes of heart failure. This study s...
Autores principales: | Kim, Morris M., Prasad, Mark, Burton, Yunwoo, Kolseth, Clinton M., Zhao, Yuanzi, Chandrashekar, Pranav, Nazer, Babak, Masri, Ahmad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492973/ https://www.ncbi.nlm.nih.gov/pubmed/37522238 http://dx.doi.org/10.1161/JAHA.123.029705 |
Ejemplares similares
-
Efficacy and safety of dofetilide and sotalol in patients with hypertrophic cardiomyopathy
por: Chen, Chris, et al.
Publicado: (2023) -
Clinical implication of pulmonary hospitalization in heart failure with preserved ejection fraction: from the TOPCAT
por: Dong, Bin, et al.
Publicado: (2020) -
Targeting efficacy of spironolactone in patients with heart failure with preserved ejection fraction: the TOPCAT study
por: Zhou, Hui‐min, et al.
Publicado: (2022) -
Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trial
por: De Marco, Corrado, et al.
Publicado: (2021) -
Endothelial Function Is Preserved in Patients with Wild-Type Transthyretin Amyloid Cardiomyopathy
por: Hashimoto, Yu, et al.
Publicado: (2023)